The finding that cleavage and shedding of the membrane-bound heparin-binding epidermal growth factor by metalloproteases contribute to the hypertrophic process offers new insights for the treatment of cardiac hypertrophy and progression to heart failure. (pages 35–40)
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Nonnatural amino acid incorporation into the methionine 214 position of the metzincin Pseudomonas aeruginosa alkaline protease
BMC Biochemistry Open Access 12 October 2005
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Bob Crimi
References
Levy, D., Garrison, R.J., Savage, D.D., Kannel, W.B. & Castelli, W.P. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N. Engl. J. Med. 322, 1561–6 (1990).
Hunter, J.J. & Chien, K.R. Signaling pathways for cardiac hypertrophy and failure. N. Engl. J. Med. 341, 1276–83 (1999).
Asakura, M. et al. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloprotease inhibitors as a potential new therapy for cardiac hypertrophy. Nature Med. 8, 35–40 (2001).
Black, R.A. & White, J.M. ADAMs: focus on the protease domain. Curr. Opin. Cell. Biol. 10, 654–659 (1998).
Prenzel, N. et al. EGF receptor transactivation by G-protein-coupled receptors requires metalloprotease cleavage of proHB-EGF. Nature 402, 884–888 (1999).
Moss, M.L. et al. Cloning of a disintegrin metalloprotease that processes precursor tumour-necrosis factor-α. Nature 385, 733–736 (1997).
Li, Y.Y. et al. Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factorα therapy. Proc. Natl. Acad. Sci. USA 97, 12746–12751 (2000).
Rogers, J.H. et al. RGS4 causes increased mortality and reduced cardiac hypertrophy in response to pressure overload. J. Clin. Invest. 104, 567–576 (1999).
Wettschureck, N. et al. Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of Gαq/Gα11 in cardiomyocytes. Nature Med. 7, 1236–12340 (2001).
Slamon, D.J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783–792 (2001).
Takemoto, M. et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J. Clin. Invest. 108, 1429–1437 (2001).
Daub, H., Weiss, F.U., Wallasch, C. & Ullrich, A. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature 379, 557–560 (1996).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Liao, J. Shedding growth factors in cardiac hypertrophy. Nat Med 8, 20–21 (2002). https://doi.org/10.1038/nm0102-20
Issue Date:
DOI: https://doi.org/10.1038/nm0102-20
